2Nilges K,Hohn H,Pilch H,et al.Human papillomavirus type 16E7peptide-directed CD8^+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.J Virol,2003,77(9):5464-5474.
3Okubo M,Saito M,Inoku H,et al.Analysis of HLA-DRB1 * 0901-binding HPV-16 E7 helper T cell epitope.J Obstet Gynaecol Res,2004,30(2):120-129.
4Kotecha MT,Afghan RK,Vasilikopoulou E,et al.Enhanced tumour growth after DNA vaccination against human papillomavirus E7 oncoprotein:evidence for tumour-induced immune deviation.Vaccine,2003,21(19-20):2506-2515.
5Herd KA,Harvey T,Khromykh AA,et al.Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.Virology.2004,319(2):237-248.
6Liu XS,Xu Y,Hardy L,et al.IL-10 mediates suppression of the CD8 Tcell IFN-gamma response to a novel viral epitope in a primed host.J Immunol,2003,171(9):4765-4772.
7Hoffmann TK,Donnenberg AD,Finkelstein SD,et al.Frequencies of tetramer^+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.Cancer Res,2002,62(12):3521-3529.
8Wiethe C,Dittmar K,Doan T,etal.Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.J Immunol,2003,170(6):2912-2922.
9Khammanivong V,Liu XS,Liu WJ,et al.Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16.Immunol Cell Biol,2003,81(1):1-7.
10Cassetti MC,McElhiney SP,Shahabi V,et al.Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.Vaccine,2004,22(3-4):520-527.
